Skip to main content

SauveBio

Flow Cytometry in Liver Toxicology Research

How Flow Cytometry Can Help With Liver

Toxicology Research

The liver is one of the most important organs in the body when it comes to breaking down drugs, chemicals, and other substances. Because of this, the liver can be affected when a drug or chemical causes toxicity. This is why liver toxicology is a very important part of drug development and safety testing. When researchers are developing new drugs, they need to understand how those drugs affect the liver. Some drugs may work well for their intended purpose but can also cause damage to liver cells. This can become a problem later in drug development, especially if the damage is not detected early on.

One way researchers can study these effects is through flow cytometry. Flow cytometry allows researchers to look at individual cells and measure different characteristics, including cell viability, cell death, oxidative stress, and immune cell activity. At SauveBio, flow cytometry is used to help researchers better understand cellular responses. These techniques can also be useful when studying liver toxicity because they allow researchers to see how different cells respond to drugs and other potentially harmful substances. If you have any questions about this matter please contact us!

Why Is Liver Toxicology Important?

As said previously, the liver plays a major role in processing drugs after they enter the body. When a drug is broken down, the liver can sometimes produce metabolites that are harmful to its own cells. Depending on the drug and how the body responds to it, this can lead to inflammation, cellular damage, or even liver failure in severe cases. One of the main concerns in drug development is drug-induced liver injury, also known as DILI. This occurs when a drug causes damage to the liver. Some drugs can cause liver injury at high doses, while others may cause unexpected reactions in certain individuals. This is why researchers need to test how drugs affect the liver before they move further into development.

Traditional testing methods can measure liver damage by looking at enzymes released from damaged cells or changes in liver tissue. These methods are useful, but they do not always explain exactly what is happening inside the cells or which cells are being affected. Flow cytometry can help provide more information by looking at individual cells instead of only measuring the sample as a whole.

How Does Flow Cytometry Help?

Flow cytometry is a technique that allows researchers to analyze thousands of individual cells in a relatively short amount of time. As cells pass through a laser, the instrument measures signals from fluorescent dyes and antibodies that have been used to label different cellular characteristics. This allows researchers to measure multiple things at once, such as cell viability, protein expression, and different signs of cellular stress. For liver toxicology, this can be useful because not every liver cell will respond to a drug in the same way. Some cells might show signs of damage, while others may remain healthy.

For example, a drug might cause damage to a small percentage of liver cells without affecting the rest. If researchers only measure the overall response of the sample, they might not fully understand what is happening. With flow cytometry, researchers can identify these different cell populations and compare how they respond to different drug concentrations. This can help researchers better understand whether a drug is causing damage and what type of cellular response is occurring.

Measuring Cell Death and Cell Viability

One of the most useful applications of flow cytometry in liver toxicology is measuring cell death and cell viability. When liver cells are exposed to a toxic drug, they may become damaged or eventually die. However, cell death does not always happen in the same way. Two common forms of cell death that researchers study are apoptosis and necrosis. Apoptosis is a controlled process where a cell goes through programmed cell death. Necrosis usually involves a loss of cell membrane integrity and can occur after severe cellular injury.

Flow cytometry can help researchers distinguish between different cell populations by using fluorescent dyes and markers. For example, Annexin V is commonly used to detect changes associated with apoptosis. When Annexin V is combined with a viability dye, researchers can identify populations that are consistent with healthy, early apoptotic, or membrane-damaged cells. This can be useful when comparing how liver cells respond to different drugs or different concentrations of the same drug.

If a higher drug concentration leads to an increase in damaged cells, researchers can use this information to better understand the relationship between drug exposure and cell toxicity. SauveBio already provides flow cytometric cell death analysis, making this one of the most relevant connections between its services and liver toxicology research.

Looking at Mitochondrial Damage and Oxidative Stress

Another important part of liver toxicology is mitochondrial damage. As you know mitochondria are the powerhouse of the cell. They produce the energy that cells need to survive and function properly. Since liver cells need a lot of energy to do their jobs, damage to their mitochondria can cause serious problems. Certain drugs can affect how mitochondria work, which can lead to cell damage or even cell death. Flow cytometry can help researchers study these changes and see if a drug is harming the mitochondria.One way researchers can do this is by looking at mitochondrial membrane potential, which helps show how well the mitochondria are functioning. Researchers can also measure reactive oxygen species, also known as ROS. These are molecules that cells naturally produce, but too much ROS can cause stress and damage to cells. Using fluorescent dyes, flow cytometry can help researchers measure these changes and better understand how a drug affects liver cells.

For example, a drug might start damaging the mitochondria before the liver cells actually begin to die. By detecting these early changes, researchers can identify possible liver toxicity before more serious damage occurs. SauveBio also has experience with fluorescence-activated mitochondrial sorting (FAMS), which allows researchers to separate and study different groups of mitochondria. This can help researchers better understand how mitochondrial damage affects liver cells.

Studying Inflammation and Immune Cell Activity

Liver toxicity is not always caused by direct damage to liver cells. In some cases, the immune system also plays a role in it as well. The liver contains several types of immune cells that help protect the body and respond to harmful substances. One example is Kupffer cells, which are macrophages found in the liver. When liver cells become damaged, immune cells may respond by becoming activated and contributing to inflammation. While inflammation is a normal part of the body’s response to injury, excessive or prolonged inflammation can lead to additional tissue damage or worse.

Flow cytometry helps researchers study immune responses by identifying different immune cells and measuring their activity. By comparing cells before and after drug exposure, researchers can identify changes that may indicate inflammation. SauveBio’s immunophenotyping services can support this research by helping identify and analyze different immune cell populations.

Using Flow Cytometry With Different Liver Models

There are several different experimental models that researchers can use to study liver toxicity. Some studies use liver cell lines, while others use primary hepatocytes, co-cultures, or more complex models such as liver spheroids and organoids. Each model has advantages and limitations depending on what the researchers are trying to study. For example, liver cell lines can be useful because they are relatively easy to grow and work with. However, they may not behave exactly like liver cells found in the human body. More complex models can sometimes provide a better representation of liver biology, but they may require additional preparation before they can be analyzed using flow cytometry.

This is important because flow cytometry generally requires cells to be in a single-cell suspension. If researchers are working with tissue samples or three-dimensional models, they may need to separate the cells before testing. The preparation process must be handled carefully because it can affect cell viability and the results of the experiment. This is why choosing the right model, selecting the correct markers, and preparing samples properly are important parts of obtaining reliable data.

How Can SauveBio Help With Liver Toxicology Research?

SauveBio is a contract research organization that focuses on flow cytometry and cell sorting. These services help researchers understand how cells react to different drugs and treatments.

For liver toxicology, SauveBio can help researchers study cell damage, cell death, and other changes in liver cells. Using flow cytometry, researchers can measure several things at once, giving them a better understanding of how a drug affects the cells.

For example, researchers may want to see if a drug is causing liver cells to die or affecting their mitochondria. Flow cytometry can help measure these changes. SauveBio also offers antibody validation services to make sure the antibodies used in experiments work properly and provide reliable results.

Another service SauveBio offers is cell sorting, also known as FACS. This allows researchers to separate certain types of cells for further testing. SauveBio can also help with planning experiments and analyzing results. Overall, these services can help researchers better understand how different drugs may affect the liver.

Why Flow Cytometry Is Useful for Liver Toxicology

Flow cytometry is not the only method used in liver toxicology research, but it can provide information that is difficult to obtain from some traditional testing methods. Instead of measuring only the overall amount of damage in a sample, researchers can examine individual cells and look at how different populations respond. This is especially useful when a drug does not affect every cell in the same way.

Researchers can also study several different characteristics, including cell death, mitochondrial stress, and immune cell activity, to get a better understanding of what may be happening.

However, flow cytometry should still be used alongside other testing methods. Measurements such as liver enzyme activity, imaging, and tissue analysis can provide additional information that helps researchers interpret their results. Combining these methods can give researchers a more complete understanding of potential liver toxicity.

Final Thoughts

Liver toxicology is an important part of drug development because researchers need to understand whether a drug could cause damage to the liver before it reaches patients. Flow cytometry helps by allowing researchers to look at individual cells and measure different responses, including cell death, mitochondrial stress, and immune cell activity. These measurements can provide useful information about how a drug affects liver cells and what may be contributing to cellular damage.

With its experience in flow cytometry, cell sorting, immunophenotyping, and assay development, SauveBio can help researchers investigate these cellular responses and support different areas of toxicology research. To learn more about how flow cytometry could support your research, visit SauveBio or contact the SauveBio team to discuss your project.

FAMS- Sorting Mitochondria

Flow Cytometry Doesn’t Stop at Cells: Sorting Mitochondria

Most people picture a flow cytometer as a machine for counting and sorting cells. But the instrument doesn’t know what a cell is. It measures particles moving single file through a laser, recording how they scatter light and which fluorescent signals they carry. If a particle can be labeled and is large enough to detect, it can be analyzed, and often sorted.

That opens the door to organelles. Nuclei are already sorted routinely ahead of single-nucleus sequencing, and chromosomes were sorted by flow decades ago to help build the first genome libraries. Mitochondria are next on that list, and they may be the most interesting of all.

Why mitochondria need a single-organelle view

A single cell can hold hundreds to thousands of mitochondria, and they are not identical. They differ in membrane potential, mass, mitochondrial DNA content, and the reactive oxygen species they produce. Some are healthy and productive. Others are damaged, depolarized, or headed for removal.

Standard assays measure the average. A Seahorse trace, a whole-cell membrane potential stain, or bulk mtDNA sequencing all blend that population into one number. If 20% of a cell’s mitochondria are dysfunctional, the average can look normal while the biology that matters is hidden inside the distribution.

What fluorescence-activated mitochondrial sorting adds

Fluorescence-Activated Mitochondrial Sorting (FAMS) applies the logic of cell sorting to isolated mitochondria. Organelles are isolated, labeled with fluorescent probes that report on features such as membrane potential or mass, and analyzed one at a time. Distinct subpopulations can then be physically separated for downstream work, including proteomics, mtDNA sequencing, metabolomics, or functional assays.

FAMS was first described by researchers at Northeastern University in MacDonald et al., Communications Biology (2019). It has been refined and applied in several publications since, including a detailed methods protocol (Sheehan et al., Methods in Molecular Biology, 2023) and studies of mitochondrial subpopulations in reproductive biology (Piasecki et al., International Journal of Molecular Sciences, 2025; Piasecki et al., Journal of Ovarian Research, 2026). SauveBio, an independent company, makes this approach available outside of an academic lab.

Where this matters

  • Aging and neurodegeneration. Accumulation of damaged mitochondria is a recurring theme in both. Sorting lets researchers ask what distinguishes the damaged fraction, rather than inferring it from averages.
  • Fertility and early development. Oocyte and embryo quality are closely tied to mitochondrial function, and the starting material is scarce. Organelle-level resolution gets more information out of every sample.
  • Cell therapy. Mitochondrial fitness in T cells is linked to persistence and function. Measuring it directly in a therapeutic product, or across treatment timepoints, is an emerging area of interest.
  • Cancer. Tumor cells vary widely in mitochondrial content, membrane potential, and mtDNA mutation load, and drug-tolerant cells often rely on mitochondrial metabolism to survive treatment. Sorting mitochondrial subpopulations lets researchers ask which organelle features track with resistance or metastatic potential, and whether a therapy shifts them.
  • Metabolic disease and toxicology. Many compounds hit mitochondria first. Seeing which subpopulation shifts, and how, is more informative than a single potency number.

What makes it hard

Mitochondria sit near the lower size limit of conventional cytometers, so separating true organelle events from debris and noise takes careful instrument setup. Isolation has to preserve organelle integrity, or the measurement reflects the prep rather than the biology. And controls matter more than usual: depolarization controls for potential-sensitive dyes, detergent lysis controls to confirm events are membrane-bound particles, and unstained isolates to define background.

None of this is out of reach, but it does reward a team that has done it many times.

Bring us your question

If your research question involves mitochondrial heterogeneity, whether in primary tissue, cultured cells, or a therapeutic product, we’d like to hear about it. Contact SauveBio today!

Flow Cytometry in Cancer Research

Flow Cytometry in Cancer Research

Cancer samples are rarely made up of one uniform cell population. A tumor may contain cancer cells, immune cells, stromal cells, endothelial cells, dead cells, and other supporting populations.

Even cancer cells within the same tumor may differ in receptor expression, proliferation, metabolism, treatment sensitivity, and signaling activity.

Flow cytometry helps researchers study this complexity by measuring individual cells rather than producing only one average result for the entire sample.

Fluorescent antibodies and functional dyes can be used to measure:

• Cell identity
• Surface-marker expression
• Intracellular proteins
• Cell viability
• Apoptosis
• Proliferation
• Cell-cycle position
• Cytokine production
• Signaling activity
• DNA content
• Drug-target expression
• Immune activation
• Immune suppression

Multiparameter flow cytometry is widely used to characterize immune populations within tumors and can analyze several markers on each individual cell.

Why Use Flow Cytometry in Cancer Research?

  1.  It Analyzes Individual Cells

Many laboratory methods measure the average signal produced by all cells in a sample.

An average measurement may hide important differences between smaller populations.

For example, a tumor sample may show moderate expression of a therapeutic target when measured in bulk. Flow cytometry may reveal that one population expresses the target strongly, another expresses it weakly, and a third population does not express it at all.

This single-cell information helps researchers determine:

• What percentage of cells express a marker
• How strongly each cell expresses the marker
• Whether separate positive and negative populations are present
• Which other markers are expressed by the same cells
• Whether a treatment affects all cells or only a subset

  1.  It Can Measure Multiple Markers Simultaneously

Cancer cells and immune cells are rarely identified using one marker alone.

A flow cytometry panel can combine lineage, viability, activation, differentiation, signaling, and functional markers.

For example, researchers may first identify live immune cells and then divide them into:

• T cells
• B cells
• NK cells
• Monocytes
• Macrophages
• Dendritic cells
• Granulocytes
• Myeloid-derived suppressor cell populations

Each population can then be examined for additional markers associated with activation, exhaustion, proliferation, cytokine production, or immune suppression.

  1.  It Can Detect Heterogeneous Populations

Cancer is biologically heterogeneous.

Differences may exist:

• Between patients
• Between primary and metastatic tumors
• Between separate regions of the same tumor
• Between treatment-responsive and resistant cells
• Between cells collected before and after therapy
• Between cancer cells and cells in the surrounding microenvironment

Flow cytometry helps identify these differences by separating the sample into measurable cellular populations.

  1. It Can Analyze Large Numbers of Cells

Flow cytometers can evaluate many individual events during one acquisition.

This allows researchers to examine population frequencies and identify smaller subsets that may not be obvious through methods that inspect fewer cells.

The number of events required depends on the frequency of the target population, the complexity of the sample, and the precision required by the experiment.

  1.  It Can Physically Isolate Selected Cells

Fluorescence-activated cell sorting can separate selected cancer or immune-cell populations from a mixed sample.

The isolated cells can then be used for:

• Cell culture
• DNA analysis
• RNA analysis
• Protein analysis
• Functional assays
• Drug testing
• Microscopy
• Clonal expansion
• Single-cell sequencing

Studying Blood Cancers with Flow Cytometry

Flow cytometry is especially important in research involving leukemia, lymphoma, myeloma, and other hematologic cancers.

Blood, bone marrow, lymph-node, and related samples can often be converted into single-cell suspensions more easily than solid tumors.

Researchers can use combinations of markers to distinguish abnormal populations from normal blood-cell development.

The National Cancer Institute’s clinical flow cytometry programs use immunophenotyping to study hematologic cancers, detect abnormal B- and T-cell populations, evaluate therapeutic targets, and monitor responses under research protocols.

Immunophenotyping Cancer Cells

Immunophenotyping is the process of identifying cells based on the proteins they express.

Flow cytometry immunophenotyping can evaluate proteins on the cell surface or inside the cell.

In blood-cancer research, immunophenotyping may be used to examine:

• Cell lineage
• Maturation stage
• Abnormal marker combinations
• Loss of expected markers
• Unusually strong or weak marker expression
• Expression of therapeutic targets
• Changes following treatment

A researcher studying an abnormal blood population may begin with broad lineage markers and then add markers associated with a specific leukemia or lymphoma subtype.

No cancer population should be identified using one marker alone when that marker may also be expressed by normal cells.

The complete marker pattern, sample type, controls, morphology, molecular findings, and research purpose should all be considered.

Studying Solid Tumors with Flow Cytometry

Solid tumors are more difficult to analyze because the tissue must first be dissociated into a single-cell suspension.

A solid-tumor sample may contain:

• Cancer cells
• T cells
• B cells
• NK cells
• Macrophages
• Monocytes
• Dendritic cells
• Granulocytes
• Fibroblasts
• Endothelial cells
• Dead cells
• Tissue debris

The dissociation method must release enough cells while preserving viability and the markers required by the study.

Mechanical or enzymatic dissociation may affect:

• Cell recovery
• Surface-marker expression
• Cell viability
• Population frequency
• Cell activation
• Fluorescence background

Researchers should validate the tissue-processing method before using it throughout a large study.

Studying the Tumor Immune Microenvironment

The tumor microenvironment includes the cancer cells and the noncancerous cells, signals, and structures surrounding them.

Immune cells are an important part of this environment and may either attack the tumor or contribute to immune suppression and cancer progression.

Multiparameter flow cytometry can characterize the immune landscape of the tumor microenvironment at the single-cell level.

Researchers may use flow cytometry to measure:

• The percentage of immune cells in the sample
• The types of immune cells present
• Activation-marker expression
• Immune-checkpoint expression
• Cytokine production
• Proliferation
• Cytotoxic proteins
• Memory and differentiation states
• Myeloid-cell phenotypes
• Regulatory or suppressive populations

T-Cell Profiling in Cancer Research

T cells are frequently studied because of their role in antitumor immunity and cancer immunotherapy.

A cancer-research flow panel may examine:

• CD4 and CD8 T-cell populations
• Naive T cells
• Central-memory T cells
• Effector-memory T cells
• Terminally differentiated T cells
• Regulatory T-cell-enriched populations
• Activated T cells
• Proliferating T cells
• Cytokine-producing T cells
• Exhaustion-associated phenotypes
• Tumor-infiltrating lymphocytes

Markers should be selected according to the specific biological question.

For example, identifying the broad CD8 T-cell population requires fewer markers than determining its activation, memory, proliferation, checkpoint, and functional states.

Regulatory T-Cell Research

Regulatory T cells are commonly investigated because they can limit immune activation.

A flow cytometry strategy may begin with live CD3-positive CD4-positive cells and then examine markers associated with a regulatory T-cell-enriched phenotype.

CD25-high and CD127-low expression may help identify a regulatory T-cell-enriched population. FOXP3 can provide additional information but requires intracellular or intranuclear staining and should only be interpreted when the fixation and permeabilization workflow is appropriate.

No single marker should be treated as definitive in every tissue or disease setting.

NK-Cell Profiling

Natural killer cells contribute to the recognition and destruction of abnormal cells.

Cancer-research panels may measure:

• NK-cell frequency
• Activation receptors
• Inhibitory receptors
• Cytotoxic proteins
• Cytokine production
• Proliferation
• Degranulation
• Immune-checkpoint expression
• Changes following therapy

The panel should distinguish NK cells from T cells and other lymphocyte populations using an appropriate combination of lineage markers.

Myeloid-Cell Profiling

Tumors can contain multiple myeloid populations, including:

• Monocytes
• Macrophages
• Dendritic cells
• Granulocytes
• Immature myeloid populations
• Myeloid-derived suppressor cell populations

These cells may participate in inflammation, antigen presentation, tissue remodeling, angiogenesis, phagocytosis, or immune suppression.

Myeloid populations can be challenging to analyze because:

• Several populations share markers
• Marker expression may be continuous
• Tissue processing can alter the phenotype
• Autofluorescence may be high
• Dead cells and debris can interfere with gating
• Definitions may vary between studies

The National Cancer Institute uses flow cytometry in projects involving immunosuppressive myeloid populations and other cancer-associated immune cells.

Measuring Immune-Checkpoint Markers

Immune-checkpoint pathways help regulate immune responses.

Cancer cells and immune cells may express checkpoint or checkpoint-related proteins that influence antitumor activity.

Flow cytometry can determine:

• Which cell population expresses the marker
• What percentage of the population is positive
• The relative level of expression
• Whether multiple checkpoint markers are co-expressed
• Whether expression changes after stimulation or treatment

Checkpoint expression should be interpreted carefully.

Expression of one marker does not automatically prove that a cell is functionally exhausted, suppressed, or unable to respond.

Researchers may need to combine surface markers with:

• Cytokine production
• Proliferation
• Degranulation
• Cytotoxicity
• Signaling measurements
• Additional differentiation markers

Measuring Therapeutic Targets

Flow cytometry can measure whether cancer or immune cells express a potential therapeutic target.

This is useful during research involving:

• Monoclonal antibodies
• Antibody-drug conjugates
• Bispecific antibodies
• CAR T-cell therapies
• CAR NK-cell therapies
• Targeted immune therapies
• Receptor-blocking drugs

Researchers can evaluate:

• The percentage of target-positive cells
• The intensity of target expression
• Differences between cancer-cell populations
• Changes following treatment
• Loss of the target in resistant cells
• Target expression on healthy cells

The National Cancer Institute uses flow cytometry to assess therapeutic targets and support studies involving cell therapies such as CAR T cells.

Receptor-Occupancy Studies

Receptor occupancy describes how much of a cellular receptor is bound by a therapeutic molecule.

Flow cytometry may be used to compare:

• Total receptor expression
• Unoccupied receptor
• Drug-bound receptor
• Receptor expression before and after treatment

Receptor-occupancy assays require carefully selected antibody clones.

An antibody used to detect the receptor may compete with the therapeutic molecule for the same binding site. If this occurs, the assay may underestimate total receptor expression or produce a misleading result.

Controls and assay-specific validation are necessary.

Measuring Cancer-Cell Viability

Viability measurements help determine whether cancer cells remain alive after treatment.

A viability dye can distinguish cells with damaged membranes from cells that exclude the dye.

Flow cytometry viability analysis may be used to compare:

• Untreated cells
• Vehicle-treated cells
• Drug-treated cells
• Different drug concentrations
• Different treatment times
• Combination therapies
• Cancer cells and noncancerous control cells

Viability should be measured within the identified cancer-cell population rather than only across the entire sample when several cell types are present.

Measuring Apoptosis

Apoptosis is a regulated form of cell death and an important endpoint in cancer drug research.

Common flow cytometry approaches include:

• Annexin V binding
• Membrane-integrity dyes
• Caspase-activity probes
• Mitochondrial membrane-potential dyes
• TUNEL-based measurements
• Intracellular apoptosis-related proteins

The National Cancer Institute lists Annexin V, TUNEL, caspase, mitochondrial, and related apoptosis assays among the flow cytometry applications used by its research facilities.

Annexin V and a membrane-integrity dye are often used together to distinguish populations consistent with:

• Viable cells
• Early apoptotic cells
• Late apoptotic or membrane-damaged cells

These classifications should be interpreted within the context of the treatment, timing, cell type, and controls.

Measuring Cell-Cycle Distribution

Cancer cells often have altered control of cell division.

DNA-binding dyes can be used to estimate the amount of DNA in each cell and determine the proportion of cells in different cell-cycle regions.

A typical DNA-content analysis may identify populations corresponding to:

• G0/G1
• S phase
• G2/M

Flow cytometry can also measure:

• DNA synthesis
• Mitotic markers
• Proliferation-associated proteins
• Cell-cycle arrest
• Sub-G1 DNA content

Cell-cycle and DNA-synthesis assays are established applications of flow cytometry in cancer-research facilities.

Cell aggregates must be excluded carefully because two cells passing together can appear to have increased DNA content.

Measuring Cell Proliferation

Flow cytometry can measure cell proliferation using:

• Dye-dilution methods
• DNA-synthesis measurements
• Intracellular proliferation markers
• Cell counts over time
• Cell-cycle analysis

Dye-dilution methods label cells with a fluorescent dye. The fluorescence becomes lower as the dye is divided between daughter cells during cell division.

Researchers can compare proliferation between:

• Treatment conditions
• Cancer-cell lines
• Immune-cell populations
• Responders and nonresponders
• Coculture conditions
• Drug-sensitive and resistant cells

Measuring Intracellular Signaling

Cancer cells may have abnormal signaling pathways that support survival, proliferation, migration, or treatment resistance.

Phospho-flow cytometry uses antibodies that recognize phosphorylated signaling proteins.

Researchers may use phospho-flow to measure:

• Baseline signaling activity
• Responses to growth factors
• Responses to cytokines
• Pathway inhibition by a drug
• Differences between cancer-cell subsets
• Signaling within immune populations
• Resistance-associated signaling

Intracellular phosphoprotein analysis is an established flow cytometry application used by NCI research facilities.

Phosphorylation can change rapidly, so sample timing, fixation, temperature, and handling must be tightly controlled.

Measuring Cytokine Production

Intracellular cytokine staining can identify which cells produce selected cytokines following stimulation.

A typical workflow may include:

  1. Stimulating the cells.
  2. Adding a secretion-blocking reagent when appropriate.
  3. Staining surface markers.
  4. Fixing the cells.
  5. Permeabilizing the cells.
  6. Staining intracellular cytokines.
  7. Identifying cytokine-producing populations by flow cytometry.

This approach can determine whether cytokine production comes from:

• CD4 T cells
• CD8 T cells
• NK cells
• Monocytes
• Macrophages
• Other selected populations

Intracellular cytokine detection is among the applications supported by NCI flow cytometry facilities.

Evaluating Cancer Drug Responses

Flow cytometry can evaluate how cancer and immune cells respond to an experimental treatment.

Possible endpoints include:

• Viability
• Apoptosis
• Necrosis
• Proliferation
• Cell-cycle arrest
• Target expression
• Receptor occupancy
• Signaling inhibition
• DNA damage
• Oxidative stress
• Mitochondrial changes
• Immune activation
• Cytokine production
• Cancer-cell killing

Measuring several endpoints can provide more information than measuring cell viability alone.

For example, a treatment may not immediately kill a cancer cell but may stop proliferation, alter signaling, or make the cell more sensitive to an immune response.

Comparing Cancer Cells with Healthy Cells

A treatment that affects cancer cells may also affect healthy cells.

Researchers may compare:

• Cancer cells and normal tissue cells
• Malignant and nonmalignant blood populations
• Tumor cells and immune cells
• Drug-sensitive and drug-resistant cancer cells
• Target-positive and target-negative cells

Flow cytometry can help determine whether an effect is selective for the cancer population or broadly toxic across the sample.

Measuring Immune-Mediated Cancer-Cell Killing

Flow cytometry can be used in coculture assays containing cancer cells and immune effector cells.

Possible effector populations include:

• T cells
• CAR T cells
• NK cells
• CAR NK cells
• Macrophages
• Engineered immune cells

The cancer cells and immune cells must be distinguishable using:

• Lineage markers
• Cell-tracking dyes
• Fluorescent proteins
• Tumor-associated markers

Researchers can then measure:

• Cancer-cell death
• Effector-cell activation
• Degranulation
• Cytokine production
• Effector-cell proliferation
• Target-cell loss
• Changes in checkpoint expression

A proper analysis should identify viability separately within the cancer-cell and immune-cell gates.

Supporting Cell-Therapy Research

Flow cytometry can support several stages of cell-therapy development.

Researchers may measure:

• Cell identity
• Cell purity
• Transduction or engineering efficiency
• CAR expression
• Viability
• Memory phenotype
• Activation state
• Exhaustion-associated markers
• Proliferation
• Cytokine production
• Degranulation
• Target-cell killing
• Persistence-related phenotypes

NCI-supported flow cytometry programs use the technology in research involving CAR T-cell therapy and other cancer clinical protocols.

Detecting Measurable Residual Disease

Measurable residual disease, or MRD, refers to a small number of cancer cells that remain after treatment and cannot necessarily be identified through routine morphological examination.

Multiparameter flow cytometry can identify residual leukemia cells by detecting leukemia-associated immunophenotypes or cell patterns that differ from normal development.

MRD status can provide important information about treatment response and risk in acute leukemia, although assay design, timing, standardization, and interpretation remain important challenges.

An MRD flow cytometry assay requires:

• A high-quality sample
• Enough acquired cells
• A validated antibody panel
• Knowledge of normal cell development
• Careful exclusion of artifacts
• Standardized instrument performance
• Trained data interpretation
• Clearly defined reporting criteria

MRD testing used for patient care must be conducted in an appropriately validated clinical laboratory. A general research flow cytometry assay should not be treated as a clinical MRD test.

Approaches to Flow Cytometry MRD Analysis

Leukemia-Associated Immunophenotype Approach

A leukemia-associated immunophenotype is identified at diagnosis.

The researcher then looks for cells with the same or a related marker pattern after treatment.

One challenge is that the cancer phenotype may change during treatment or relapse.

Different-from-Normal Approach

The post-treatment sample is compared with expected patterns of normal cell maturation.

Cells with abnormal combinations, intensities, or developmental patterns may be investigated as possible residual disease.

This approach requires strong knowledge of normal and regenerating bone-marrow populations.

Detecting Rare Cancer-Associated Cells

Flow cytometry may be used to study rare cancer-associated populations, including:

• Residual leukemia cells
• Cancer stem-like populations
• Rare treatment-resistant cells
• Circulating tumor cells
• Small metastatic populations
• Rare immune subsets

Rare-event analysis is vulnerable to false-positive events caused by:

• Debris
• Dead cells
• Doublets
• Cell aggregates
• Nonspecific staining
• Autofluorescence
• Compensation or unmixing errors
• Sample contamination
• Acquisition instability

Enough total events must be acquired to support the intended analysis.

Studying Circulating Tumor Cells

Circulating tumor cells are cancer-associated cells found in the bloodstream.

They may be greatly outnumbered by normal blood cells, which makes their detection and purification challenging. Cytometric strategies often combine positive markers associated with the tumor with exclusion markers for unwanted blood populations.

A circulating-tumor-cell research strategy may include:

• Enrichment before flow cytometry
• Exclusion of dead cells
• Exclusion of leukocytes
• Positive tumor-associated markers
• Multiple confirmation markers
• Careful rare-event controls
• Sorting for downstream characterization

Marker-based detection can miss tumor cells that do not express the selected markers. Researchers should avoid assuming that every circulating tumor cell will have one uniform phenotype.

Cancer Stem-Like Cell Research

Some cancer studies investigate smaller populations with characteristics associated with self-renewal, treatment resistance, tumor initiation, or recurrence.

Flow cytometry may be used to identify and sort populations based on:

• Surface-marker combinations
• Enzyme activity
• Dye-efflux properties
• Metabolic probes
• Reporter expression
• Functional characteristics

A marker-defined population should not automatically be described as a functional cancer stem-cell population.

Functional assays are usually needed to determine whether the cells actually demonstrate the proposed biological behavior.

Cell Sorting in Cancer Research

Fluorescence-activated cell sorting can isolate selected cancer or immune-cell populations.

Researchers may sort:

• Tumor cells from immune cells
• Target-positive and target-negative cancer cells
• Drug-resistant populations
• Immune-cell subsets
• Reporter-positive engineered cells
• Live cancer stem-like populations
• Single cancer cells
• Rare residual populations

Sorted cells may then be used for:

• Sequencing
• Cell culture
• Drug-response assays
• Protein analysis
• Functional testing
• Imaging
• Clonal expansion

The panel should be designed using live-cell-compatible markers when the sorted cells need to remain alive.

Sample Types Used in Cancer Flow Cytometry

Cancer research may involve:

• Peripheral blood
• Bone marrow
• Lymph-node samples
• Tumor biopsies
• Surgically removed tumors
• Fine-needle aspirates
• Pleural or abdominal fluids
• Cell lines
• Patient-derived cells
• Organoids
• Spheroids
• Xenograft-derived tissues
• Coculture systems

Each sample type presents different challenges.

Blood and bone marrow may contain large numbers of red blood cells.

Solid tumors require dissociation.

Fluids may contain low cell numbers.

Organoids and spheroids require disruption into a single-cell suspension.

Cell lines may not represent the heterogeneity of a patient tumor.

Cancer Cell Lines

Cancer cell lines are commonly used during early assay development because they are easier to grow and standardize than many primary tumor samples.

They may be useful for:

• Antibody testing
• Drug screening
• Apoptosis assays
• Cell-cycle studies
• Signaling experiments
• Target-expression analysis
• Coculture development
• Sorting optimization

However, long-established cell lines may differ from primary tumors in genetics, growth, metabolism, receptor expression, and treatment response.

Important findings should be evaluated in more biologically relevant models when possible.

Patient-Derived Tumor Samples

Patient-derived samples may better represent actual tumor heterogeneity but can be more difficult to process.

Challenges may include:

• Limited sample size
• Low viability
• Variable tissue composition
• Prior treatment effects
• High autofluorescence
• Large amounts of debris
• Donor-to-donor variability
• Unpredictable marker expression
• Delays between collection and processing

The workflow should be designed to preserve as much usable material as possible.

Organoids and Three-Dimensional Tumor Models

Organoids and spheroids may provide more complex models than standard two-dimensional cell cultures.

Flow cytometry can be used after the model is dissociated into individual cells.

Researchers may examine:

• Cancer-cell viability
• Drug penetration effects
• Treatment-resistant populations
• Immune-cell infiltration
• Cancer and stromal-cell interactions
• Target expression
• Cellular composition

The dissociation method must be validated because it may cause cell loss or alter the markers being measured.

A Basic Cancer Flow Cytometry Workflow

A cancer flow cytometry experiment may include the following steps:

  1. Define the biological question.
  2. Select the sample type.
  3. Identify the cell populations that must be measured.
  4. Select the required markers.
  5. Design the fluorophore panel.
  6. Prepare the necessary controls.
  7. Convert the sample into a single-cell suspension.
  8. Count the cells and measure viability.
  9. Stain the cells.
  10. Wash and resuspend the sample.
  11. Configure and quality-check the instrument.
  12. Acquire enough events.
  13. Apply the gating strategy.
  14. Review compensation or spectral unmixing.
  15. Compare the experimental groups.
  16. Confirm important findings using appropriate controls or additional methods.

Step 1: Define the Biological Question

The flow cytometry panel should be built around a specific question.

Examples include:

• Does a drug cause apoptosis in the cancer cells?
• Does treatment reduce receptor expression?
• Which immune cells are present in the tumor?
• Are CD8 T cells activated after therapy?
• Does a resistant cancer population remain after treatment?
• Do cancer cells express the intended therapeutic target?
• Which cells produce a selected cytokine?
• Can a rare cancer-cell population be isolated?

A panel should not begin with the question, “How many markers can be added?”

It should begin with the minimum markers needed to answer the biological question accurately.

Step 2: Select the Population-Identification Markers

The panel must distinguish the population of interest from other cells in the sample.

A solid-tumor immune-profiling panel may require markers to separate:

• Immune and nonimmune cells
• T cells and other lymphocytes
• Myeloid and lymphoid populations
• Cancer cells and stromal cells
• Live and dead cells

A blood-cancer panel may require markers that identify:

• Lineage
• Maturation
• Abnormal antigen combinations
• Therapeutic targets
• Residual abnormal populations

Step 3: Add Functional Markers

After the cell populations can be identified, functional markers may be added.

These may measure:

• Activation
• Exhaustion-associated phenotypes
• Proliferation
• Cytotoxicity
• Cytokine production
• Signaling
• Apoptosis
• Cell cycle
• Receptor occupancy
• Drug response

Adding functional markers before the populations can be identified may produce data that are difficult to interpret.

Step 4: Select the Fluorophores

Fluorophore selection should consider:

• Marker-expression level
• Fluorophore brightness
• Co-expression patterns
• Spillover or spectral similarity
• Instrument configuration
• Sample autofluorescence
• Fixation compatibility
• Tandem-dye stability
• Importance of the marker

Dim or critical markers generally require fluorophores that provide strong separation.

Highly expressed markers may be assigned to more moderate fluorophores.

Markers expressed on the same cells should not automatically be paired with fluorophores that create severe spread into one another.

Conventional and Spectral Flow Cytometry in Cancer Research

Conventional and spectral cytometers can both support cancer research.

Conventional flow cytometry may be suitable for:

• Established panels
• Smaller experiments
• Routine cell-line assays
• Basic immune profiling
• Apoptosis and cell-cycle studies
• Validated blood-cancer panels

Spectral flow cytometry may be particularly useful for:

• High-parameter immune profiling
• Complex tumor samples
• Highly autofluorescent cells
• Limited samples that cannot be divided across several tubes
• Measuring many markers on the same cells

Spectral flow does not remove the need for thoughtful panel design, antibody titration, controls, and data review.

High-Parameter Flow Cytometry in Cancer Research

High-parameter flow cytometry allows researchers to evaluate many markers on the same cells.

It may be useful for studying:

• Tumor immune heterogeneity
• Detailed T-cell states
• Myeloid diversity
• Immune-checkpoint combinations
• Treatment-response signatures
• Rare populations
• Cell-therapy products
• Multiple cancer and immune populations in one sample

More parameters do not automatically create a better experiment.

Every marker should have a clear role in identifying a population, answering the biological question, or supporting data interpretation.

Important Controls for Cancer Flow Cytometry

  1. Unstained Control

The unstained control shows the natural autofluorescence of the sample.

This is particularly important for tumor cells, macrophages, granulocytes, fixed samples, and dissociated tissues.

  1. Single-Stained Controls

Single-stained controls are used for conventional compensation or spectral-reference controls.

A suitable control is generally needed for each fluorophore.

  1. Fluorescence-Minus-One Controls

An FMO control contains every fluorophore except the marker being evaluated.

FMOs may be useful for:

• Dim markers
• Continuous expression patterns
• Rare populations
• Checkpoint markers
• Activation markers
• Gates affected by fluorescence spread

  1. Viability Controls

A dead-cell control can help establish the viability-dye-positive population.

  1. Biological Positive and Negative Controls

These may include:

• Untreated cells
• Vehicle controls
• Known target-negative cells
• Known target-positive cells
• Stimulated immune cells
• Drug-sensitive cells
• Drug-resistant cells
• Untransfected cells
• Reporter-negative cells

  1. Isotype Controls

Isotype controls may help investigate certain nonspecific-binding problems, but they do not replace FMOs, biological controls, or unstained controls for routine gate placement.

A General Gating Strategy for Cancer Samples

A cancer flow cytometry gating strategy may include:

  1. Time Gate

A time gate can identify interruptions, clogs, pressure changes, or unstable acquisition periods.

  1. Cell and Debris Gate

Forward and side scatter may help separate intact cells from obvious debris.

This gate should not be so restrictive that it removes small, dying, or unusually shaped target cells that are relevant to the study.

  1. Singlet Gate

Doublets and aggregates should be excluded using pulse-area, height, or width measurements.

  1. Viability Gate

Dead cells should be removed when the analysis focuses on live-cell phenotypes.

  1. Broad Population Gate

Examples include:

• Immune versus nonimmune cells
• Hematopoietic versus nonhematopoietic cells
• Cancer cells versus immune cells
• Lymphoid versus myeloid cells

  1. Lineage and Subset Gates

The broad populations can then be divided into the required lineages and subsets.

  1. Functional-Marker Analysis

Activation, checkpoint, proliferation, apoptosis, cytokine, or signaling markers should be evaluated within clearly identified populations.

Autofluorescence in Cancer Samples

Autofluorescence is naturally produced by cells and tissues.

It may be particularly strong in:

• Tumor cells
• Macrophages
• Granulocytes
• Lung tissue
• Digestive tissue
• Brain tissue
• Dead or damaged cells
• Fixed samples

Autofluorescence can reduce the separation between negative cells and dim positive cells.

Researchers may address it through:

• Proper unstained controls
• Careful fluorophore selection
• Exclusion of dead cells
• Consistent sample processing
• Spectral autofluorescence extraction when appropriate
• Avoiding dim fluorophores in highly autofluorescent regions

Common Problems in Cancer Flow Cytometry

  1. Low Viability

Possible causes include:

• Delayed sample processing
• Harsh tissue dissociation
• Long staining procedures
• Incorrect buffers
• Excessive centrifugation
• Toxic treatments
• Poor starting-sample quality

  1. Excessive Debris

Possible causes include:

• Necrotic tumors
• Overly harsh dissociation
• Cell death during storage
• Incomplete washing
• Inappropriate filtering

  1. Cell Clumping

Possible causes include:

• Released DNA from dead cells
• Incomplete tissue dissociation
• High cell concentration
• Inadequate mixing
• Damaged cells
• Long sample-storage periods

  1. Weak Marker Expression

Possible causes include:

• Low antigen density
• Enzymatic removal of the marker
• Incorrect antibody clone
• Poor fluorophore assignment
• Under-titrated antibody
• Treatment-related target loss

  1. High Background

Possible causes include:

• Dead cells
• Fc-receptor binding
• Excess antibody
• Inadequate washing
• Autofluorescence
• Nonspecific staining
• Poor control selection

  1. Unexpected Population Frequencies

Possible causes include:

• Selective cell loss
• Incomplete tissue dissociation
• Incorrect gating
• Unequal sample handling
• Low event counts
• Treatment-related cell death
• Batch effects

Limitations of Flow Cytometry in Cancer Research

  1. It Requires a Single-Cell Suspension

Standard flow cytometry does not preserve the original location of cells within a tissue.

Researchers may know which cell populations are present but not where they were positioned in relation to the tumor.

Imaging, histology, or spatial methods may be needed to provide tissue-location information.

  1. Tissue Processing Can Change the Sample

Dissociation can cause:

• Cell loss
• Cell death
• Receptor cleavage
• Cellular activation
• Changes in population frequency

  1. Marker Expression Does Not Always Equal Function

A cell expressing an activation or exhaustion-associated marker may not necessarily behave as expected.

Functional assays may be needed.

  1. Rare-Event Analysis Is Vulnerable to Artifacts

Debris, doublets, nonspecific staining, and acquisition instability can resemble rare cells.

  1. Panels Require Extensive Validation

An antibody that works alone may behave differently within a large panel.

  1. Flow Cytometry Does Not Replace Every Other Method

Cancer research may also require:

• Histology
• Imaging
• Sequencing
• Cytogenetics
• Molecular testing
• Functional assays
• Protein analysis
• Clinical evaluation

Flow cytometry is most powerful when used as part of a broader experimental strategy.

Best Practices for Cancer Research Using Flow Cytometry

To improve data quality:

  1. Define the biological question before designing the panel.
  2. Identify the minimum markers needed to answer the question.
  3. Validate the tissue-dissociation method.
  4. Process samples consistently and promptly.
  5. Count the cells and measure viability.
  6. Include a suitable viability dye.
  7. Titrate every antibody.
  8. Match fluorophore brightness to marker expression.
  9. Evaluate sample autofluorescence.
  10. Include appropriate unstained and single-stained controls.
  11. Use FMOs for gates that are difficult to define.
  12. Include biological positive and negative controls.
  13. Exclude debris, doublets, and dead cells.
  14. Acquire enough events for the populations being studied.
  15. Review compensation or spectral unmixing before biological interpretation.
  16. Measure treatment effects within clearly identified populations.
  17. Keep tissue processing consistent across comparison groups.
  18. Record instrument settings and quality-control results.
  19. Validate the complete panel rather than only individual antibodies.
  20. Confirm important results using functional or complementary methods.
  21. Use validated clinical workflows when results are intended for patient care.
  22. Document the complete gating and analysis strategy.

Improving Cancer Research Through Flow Cytometry

Flow cytometry provides a flexible method for studying cancer cells, immune cells, and the interactions between them.

It can be used to investigate blood cancers, solid tumors, the tumor immune microenvironment, drug responses, apoptosis, proliferation, signaling, therapeutic targets, residual disease, and cell-therapy products.

Its greatest advantage is the ability to measure several characteristics on individual cells within a complex sample.

This can reveal rare populations and biological differences that may be hidden by measurements that average all cells together.

However, reliable cancer flow cytometry requires careful sample preparation, validated antibodies, appropriate controls, sufficient event collection, thoughtful gating, and accurate interpretation.

When these factors are carefully controlled, flow cytometry can provide detailed information about cancer-cell identity, immune responses, treatment effects, and cellular heterogeneity throughout the research process.

Conventional, Spectral, and High-Parameter Flow Cytometry

Conventional, Spectral, and High-Parameter Flow Cytometry: Differences and Uses

Flow cytometry allows researchers to examine physical and biological characteristics of individual cells within a mixed sample. Fluorescently labeled antibodies, viability dyes, DNA-binding dyes, and functional probes can be used to measure protein expression, cell viability, signaling, proliferation, cell cycle, and other cellular properties.

However, not every flow cytometer collects fluorescence in the same way. Conventional and spectral flow cytometers use different optical and mathematical approaches to separate fluorescent signals.

High-parameter flow cytometry is slightly different because it does not describe one specific detection technology. Instead, it describes an experiment that measures a large number of markers or cellular characteristics simultaneously.

Understanding these differences helps researchers select an instrument, build an appropriate antibody panel, prepare the correct controls, and avoid unnecessary complexity.

The Most Important Difference to Understand

Conventional flow cytometry and spectral flow cytometry describe how an instrument detects and separates fluorescent signals.

High-parameter flow cytometry describes how many characteristics are measured on each cell.

This means:

• A conventional flow cytometer can perform a high-parameter experiment.
• A spectral flow cytometer can perform a high-parameter experiment.
• A spectral flow cytometer can also run a small, low-parameter panel.
• High-parameter flow cytometry is not automatically spectral flow cytometry.

Published optimized panels demonstrate that large fluorescence panels can be developed using conventional instruments, while spectral systems provide another method for supporting complex multiparameter experiments.

What Is Conventional Flow Cytometry?

Conventional flow cytometry measures fluorescence using optical filters that divide emitted light into selected wavelength ranges.

When a fluorophore is excited by a laser, it emits light across a range of wavelengths. A conventional cytometer uses dichroic mirrors and filters to direct selected portions of that fluorescence toward individual detectors.

Each detector is generally associated with a specific fluorescence channel. For example, a detector may be configured to collect the wavelengths commonly associated with FITC, PE, APC, or another fluorophore.

The instrument does not measure only the intended fluorophore in each channel. Fluorophores have broad emission spectra, so fluorescence from one dye may also enter detectors intended for other dyes. This overlap is called spillover. Conventional flow cytometry uses compensation to mathematically correct for this signal overlap.

What Is Compensation?

Compensation estimates how much fluorescence from one fluorophore appears in detectors assigned to other fluorophores.

Single-stained controls are used to measure the spillover pattern of each dye. The resulting compensation matrix is then applied to the experimental samples.

Compensation does not physically remove fluorescence or improve the original signal. It mathematically separates the measured signals so that each fluorescence parameter can be interpreted more accurately.

Proper compensation depends on:

• Bright and appropriate single-stained controls
• Controls that match the experimental fluorophores
• Correct detector settings
• Consistent sample processing
• Proper control gating
• Stable instrument performance

Poor compensation can make negative populations appear distorted, increase population spreading, or make it difficult to identify dimly expressed markers.

Why Use Conventional Flow Cytometry?

  1. It Works Well for Established Panels

Conventional flow cytometry is often appropriate when a laboratory already has a validated panel that performs reliably on a conventional instrument.

Moving an established assay to another platform may require new optimization, controls, fluorophore assignments, and acceptance criteria. If the current panel already answers the biological question, changing technologies may not provide a meaningful advantage.

  1. It Can Be Easier for Smaller Panels

A small panel may only need a viability dye and several surface or intracellular markers.

For these experiments, a conventional instrument may provide all the required information without the added reference controls and unmixing workflow associated with spectral cytometry.

Examples may include:

• Basic T-cell profiling
• Simple viability assays
• Cell-cycle analysis
• Apoptosis assays
• Receptor-occupancy assays
• Routine expression analysis
• Small intracellular cytokine panels

  1. It Is Commonly Available

Many laboratories, clinical facilities, and research cores already have conventional flow cytometers.

Using an available and familiar platform may reduce scheduling difficulties, training requirements, and the need to transfer data between different analysis systems.

  1. It Supports Standardized Workflows

Conventional flow cytometry has been used for many years in research and clinical laboratories.

Researchers may already have:

• Validated antibody combinations
• Established compensation controls
• Instrument quality-control procedures
• Standard operating procedures
• Historical data for comparison
• Experienced operators and analysts

These existing resources can make conventional flow cytometry a strong choice for routine or regulated workflows.

  1. It Can Still Support Large Panels

Conventional flow cytometry is not limited to basic four- or eight-color experiments.

Instruments with multiple lasers and detectors can support large multicolor panels. Published examples include fluorescence panels measuring approximately 28 colors and 30 total parameters on individual cells.

The ability to run a large panel depends on the instrument configuration, fluorophore selection, antigen expression, reagent quality, and panel-design experience.

  1. It May Be Appropriate for Cell Sorting

Many fluorescence-activated cell sorters use conventional optical configurations.

If the goal is to physically isolate a defined population for culture, sequencing, microscopy, or functional testing, the available conventional sorter may be the most practical choice.

Limitations of Conventional Flow Cytometry

  1. Limited Fluorescence Collection

A conventional detector collects fluorescence within a selected wavelength range rather than recording the complete emission pattern.

Information outside that detector range is not used to identify the fluorophore.

  1. Increasing Panel Complexity

As more fluorophores are added, spillover and spreading error become more difficult to manage.

Researchers must carefully assign fluorophores based on:

• Antigen density
• Fluorophore brightness
• Spillover patterns
• Co-expression
• Detector sensitivity
• Biological importance

  1. Fixed Optical Configurations

Conventional instruments use specific filters and detectors.

A fluorophore may not be ideal for an instrument if the correct laser or filter configuration is unavailable. Changing filters may also require technical support or additional validation.

  1. Autofluorescence Can Affect Sensitivity

Cells and tissues naturally produce fluorescence.

High-autofluorescence samples may make it difficult to distinguish dim positive populations from the negative background, particularly when the autofluorescence falls within the same detector range as the fluorophore.

What Is Spectral Flow Cytometry?

Spectral flow cytometry collects fluorescence across a broad range of wavelengths using multiple detectors.

Instead of assigning one narrow detector channel to each fluorophore, the system measures the shape of the fluorophore’s emission across an array of detectors.

Each fluorophore produces a characteristic spectral signature. Spectral-unmixing software compares the combined fluorescence collected from each cell with reference signatures from single-stained controls. It then estimates the contribution of each fluorophore to the total measured signal.

What Is Spectral Unmixing?

Spectral unmixing is the mathematical process used to separate overlapping fluorescence signatures.

Before experimental samples are unmixed, the system needs reference controls representing the spectral signature of every fluorophore in the panel.

The measured signal from each experimental cell is treated as a combination of those reference signatures.

The software then calculates how much of the total fluorescence came from each fluorophore.

Spectral unmixing may also treat autofluorescence as an additional spectral signature. This can help separate cellular autofluorescence from fluorescent labels when appropriate controls and instrument settings are used.

Why Use Spectral Flow Cytometry?

  1. It Uses More of the Fluorescence Emission Pattern

Spectral cytometers collect fluorescence across multiple detectors rather than relying only on one selected wavelength range.

This provides additional information about the shape of each fluorophore’s emission.

Two fluorophores may have similar peak-emission wavelengths but different overall spectral shapes. A spectral instrument may be able to distinguish them when their complete signatures are sufficiently different.

  1. It Can Support Larger Panels

Spectral detection can provide more flexibility when building panels containing many fluorophores.

This is especially useful when researchers need to measure numerous lineage, differentiation, activation, functional, and viability markers in one sample.

However, spectral flow cytometry does not eliminate spillover-related spreading. Fluorophores with highly similar signatures can still be difficult to separate, particularly when one marker is very bright and the other is dim.

  1. It Can Help Manage Autofluorescent Samples

Autofluorescence is common in:

• Macrophages
• Monocytes
• Granulocytes
• Tumor samples
• Lung tissue
• Brain tissue
• Digestive tissues
• Fixed samples
• Aged or damaged cells

When autofluorescence has a reproducible spectral signature, spectral unmixing may separate it from the labeled fluorophores as an independent component.

This can improve the distinction between autofluorescent cells and truly positive populations. It does not guarantee that all autofluorescence problems will disappear.

  1. It Can Provide Greater Fluorophore Flexibility

Spectral systems may allow researchers to use fluorophore combinations that would be difficult to separate using only conventional detector channels.

Panel design is still necessary, but researchers can consider the complete spectral signatures instead of only the primary detector associated with each dye.

  1. It May Reduce the Need to Split Samples Across Panels

When enough markers can be measured in one tube, researchers may not need to divide a limited sample across several smaller panels.

This can be particularly valuable for:

• Small biopsies
• Pediatric samples
• Rare clinical samples
• Fine-needle aspirates
• Low-yield tissue dissociations
• Rare-cell studies
• Longitudinal studies with limited sample volumes

Keeping markers in one panel also allows researchers to measure relationships between those markers on the same individual cells.

  1. It Can Improve the Characterization of Heterogeneous Samples

Tumors, blood, bone marrow, inflamed tissues, and dissociated organs can contain many overlapping cell populations.

Spectral flow cytometry can support panels that identify major lineages and then describe activation, differentiation, exhaustion, memory, signaling, or functional states within those lineages.

Limitations of Spectral Flow Cytometry

Reference Controls Must Be Accurate

Spectral unmixing depends on accurate reference signatures.

Controls should match the experimental fluorophores and should be prepared under conditions that reproduce important effects such as fixation, permeabilization, tandem-dye behavior, and sample autofluorescence.

Unmixing Does Not Eliminate Spreading Error

Spectral cytometry can distinguish fluorophores using their complete signatures, but it cannot fully remove the statistical uncertainty produced when fluorescence signals overlap.

Poor fluorophore assignments can still make dim markers difficult to resolve.

Complex Panels Require Significant Optimization

Large spectral panels may require:

• Antibody titration
• Fluorophore testing
• Reference-control optimization
• Autofluorescence controls
• Spillover-spreading evaluation
• Marker-assignment changes
• Repeated panel testing
• Consistent sample processing

Instrument Access and Training May Be Limited

Not every laboratory has a spectral instrument or staff members experienced in spectral unmixing.

Researchers must also understand how to identify unmixing errors rather than assuming that software-generated results are automatically correct.

Tandem Dyes Can Create Variability

Tandem dyes may change because of light exposure, fixation, storage, temperature, or reagent degradation.

If the spectral signature of the experimental tandem dye differs from the reference control, unmixing may be less accurate.

What Is High-Parameter Flow Cytometry?

High-parameter flow cytometry refers to measuring many characteristics on each individual cell.

There is no universal number of colors that officially defines a panel as high-parameter. The term generally describes panels that go beyond basic immunophenotyping and combine many lineage, subset, activation, functional, and viability markers.

High-parameter panels containing approximately 25, 28, 30, 40, or more colors have been reported, although the number that can be used successfully depends on the instrument, reagents, sample type, and assay design.

High-parameter flow cytometry can be performed using:

• Conventional flow cytometry
• Spectral flow cytometry
• A conventional cell sorter
• A spectral cell sorter, when available

Why Use High-Parameter Flow Cytometry?

  1. To Identify More Cell Populations in One Sample

A basic panel may identify only major populations such as T cells, B cells, NK cells, and monocytes.

A high-parameter panel can identify those lineages and divide them into smaller subsets.

For example, a T-cell panel may evaluate:

• CD4 and CD8 lineages
• Naive cells
• Central-memory cells
• Effector-memory cells
• Terminally differentiated cells
• Regulatory T cells
• Activated cells
• Proliferating cells
• Exhaustion-associated phenotypes
• Cytokine-producing cells

  1. To Preserve Limited Samples

Dividing a sample across several smaller panels requires more cells.

A high-parameter panel can measure more markers in one tube, preserving cells for additional experiments or reducing the total sample volume required.

  1. To Measure Marker Relationships on the Same Cells

Separate panels cannot always show whether markers were expressed by the same individual cell.

A high-parameter panel can determine whether a single cell simultaneously expresses a particular combination of lineage, activation, checkpoint, trafficking, and functional markers.

  1. To Detect Rare Populations

Rare populations may be difficult to compare across several separate tubes.

Including the required identification and characterization markers in one panel allows researchers to gate the rare population and examine its phenotype directly.

Accurate rare-cell analysis still requires enough total events, appropriate controls, and careful exclusion of debris, dead cells, doublets, and acquisition artifacts.

  1. To Study Cellular Heterogeneity

Biological samples rarely contain completely uniform populations.

High-parameter flow cytometry can reveal smaller subpopulations that may be missed when only a few markers are measured.

This is particularly useful in:

• Cancer research
• Immunology
• Vaccine research
• Infectious-disease research
• Autoimmune-disease research
• Cell-therapy development
• Drug-response studies
• Translational biomarker research

  1. To Reduce Differences Between Separate Panels

When several panels are used, differences in cell numbers, staining, sample handling, and acquisition can complicate comparisons.

A single high-parameter panel measures all included markers under the same staining and acquisition conditions.

  1. To Support Exploratory Research

High-parameter data can be examined using manual gating and computational approaches such as dimensionality reduction, clustering, and population-discovery tools.

These methods may help identify patterns that were not obvious when the experiment was originally designed.

Computational findings should still be reviewed for technical artifacts and interpreted using biological knowledge.

Limitations of High-Parameter Flow Cytometry

  1. Panel Design Becomes More Difficult

Every additional fluorophore creates more possible signal interactions.

A high-parameter panel requires thoughtful placement of:

• Bright fluorophores
• Dim fluorophores
• Highly expressed markers
• Rare markers
• Co-expressed markers
• Critical exclusion markers

  1. More Controls May Be Required

High-parameter experiments commonly require:

• Unstained controls
• Single-stained controls
• Viability controls
• Fluorescence-minus-one controls
• Biological positive and negative controls
• Autofluorescence controls
• Instrument quality-control samples

Not every marker requires an FMO control, but FMOs can be especially useful when expression is continuous, dim, or difficult to separate from the negative population.

  1. Data Analysis Is More Complex

Traditional sequential gating remains useful, but the number of possible marker combinations increases rapidly as parameters are added.

Analysts must carefully document gating decisions and avoid selecting populations based only on visually interesting patterns.

  1. More Parameters Do Not Automatically Produce Better Data

Adding markers that do not support the biological question can increase cost and complexity without improving the study.

A smaller, well-validated panel may produce more reliable and interpretable results than a larger panel with weak controls or poorly selected markers.

  1. Validation Requires More Work

Researchers must evaluate whether each marker still performs properly within the complete panel.

An antibody that works well by itself may become difficult to interpret after other fluorophores are added.

Conventional Versus Spectral Flow Cytometry

The main difference is the way fluorescence is collected and mathematically separated.

Conventional flow cytometry:

• Uses optical filters to collect selected wavelength ranges
• Assigns fluorescence primarily to individual detector channels
• Uses compensation to correct spillover
• Works well for routine, established, and smaller panels
• Can also support high-parameter panels on appropriately configured instruments

Spectral flow cytometry:

• Collects fluorescence across an array of detectors
• Uses the overall spectral signature of each fluorophore
• Uses spectral unmixing rather than conventional compensation
• Can model autofluorescence as an additional signature
• Often provides greater flexibility for complex panels
• Requires accurate spectral-reference controls

Both approaches require careful panel design, antibody titration, quality controls, and data review.

Spectral Versus High-Parameter Flow Cytometry

Spectral flow cytometry is an instrument-detection approach.

High-parameter flow cytometry is an experimental approach that measures many parameters.

A spectral experiment is not necessarily high-parameter. A researcher could run a six-color panel on a spectral instrument.

A high-parameter experiment is not necessarily spectral. A researcher could run a validated 20- or 30-color panel on a conventional instrument with the appropriate lasers, detectors, filters, and fluorophores.

The terms describe different parts of the workflow and should not be used interchangeably.

When Should You Use Conventional Flow Cytometry?

Conventional flow cytometry may be the best choice when:

• The panel is small or moderately sized
• The assay is already validated
• Historical data were collected on the same platform
• The necessary lasers and filters are available
• The sample does not have problematic autofluorescence
• The laboratory has experienced conventional-flow operators
• A conventional sorter is needed
• A spectral instrument is not available
• The biological question does not require a larger panel

When Should You Use Spectral Flow Cytometry?

Spectral flow cytometry may be useful when:

• The panel contains many fluorophores
• Several fluorophores have overlapping emission patterns
• The sample has substantial autofluorescence
• The sample is limited and cannot be divided across multiple tubes
• Many cell populations must be identified in one sample
• Relationships between numerous markers must be measured on the same cells
• The laboratory has the controls and experience needed for accurate unmixing

When Should You Use High-Parameter Flow Cytometry?

High-parameter flow cytometry may be appropriate when:

• The sample contains many related cell populations
• Rare subsets must be identified and characterized
• Sample availability is limited
• Multiple panels would require too many cells
• Many markers must be compared on the same cells
• The study focuses on immune heterogeneity
• The experiment evaluates activation, differentiation, memory, exhaustion, or functional states
• The research question justifies the additional complexity

Choosing the Right Approach

The most advanced instrument is not automatically the best instrument for every experiment.

The choice should be based on:

  1. The biological question
  2. The number of markers required
  3. The amount of sample available
  4. The expected level of autofluorescence
  5. The expression level of each marker
  6. The need for cell sorting
  7. Available instruments and detector configurations
  8. Staff experience
  9. Control requirements
  10. Data-analysis capabilities
  11. Study timelines and budget
  12. Whether the assay must be validated or transferred

Researchers should begin by identifying the minimum set of markers required to answer the question.

Additional markers should be included when they provide useful biological information, improve population identification, or reduce the need for separate panels.

Best Practices for Conventional, Spectral, and High-Parameter Flow Cytometry

To improve data quality:

  1. Define the biological question before selecting the platform.
  2. Confirm the lasers and detectors available on the instrument.
  3. Titrate every antibody under the intended assay conditions.
  4. Match fluorophore brightness to antigen expression.
  5. Avoid placing strongly co-expressed markers on fluorophores with problematic overlap.
  6. Include an appropriate viability dye.
  7. Use accurate single-stained controls.
  8. Match controls to fixation and permeabilization conditions.
  9. Evaluate autofluorescence before finalizing the panel.
  10. Use FMOs for gates that are difficult to define.
  11. Monitor instrument performance and quality control.
  12. Use consistent staining, washing, and acquisition procedures.
  13. Acquire enough events for the populations being studied.
  14. Review compensation or unmixing results before biological analysis.
  15. Validate the complete panel rather than testing markers only individually.
  16. Document the gating and analysis strategy.
  17. Confirm major findings with appropriate biological controls.
  18. Avoid adding parameters that do not contribute to the research question.

Selecting the Best Flow Cytometry Method

Conventional flow cytometry remains a dependable option for routine assays, established panels, cell sorting, and experiments that do not require a large number of markers.

Spectral flow cytometry collects broader fluorescence information and uses spectral unmixing to separate fluorophore signatures. It can provide additional flexibility for complex panels and may help manage samples with significant autofluorescence.

High-parameter flow cytometry allows researchers to examine many characteristics on the same individual cells. It can be performed using conventional or spectral instruments and is particularly useful for complex, heterogeneous, rare, or limited samples.

The best approach is not necessarily the one that measures the most markers. It is the one that answers the biological question with appropriate controls, reliable staining, accurate signal separation, and interpretable data.

Flow Cytometry: The Cell-Sorting Superpower 

Flow cytometry sounds super complicated, but the idea is simple: It helps scientists look at millions of individual cells and ask, “Who are you, what are you doing, and are you healthy?”

That makes it an important tool in biotech, especially in:

  • Cell and gene therapy
  • Oncology
  • Immunotherapy
  • Neuroscience
  1. Cell and Gene Therapy

Cell and gene therapy is all about creating powerful, targeted treatments using living cells.

Flow cytometry helps teams check:

  • What types of cells are in the sample
  • Whether engineered cells were made as intended
  • If the cells are alive and healthy
  • If the final therapy looks consistent

For example, in CAR-T therapy, flow cytometry can help measure CAR-positive T cells, CD4/CD8 ratios, and immune-cell activation.

Basically, before cells go into a patient, flow helps make sure they are the right cells doing the right job.

  1. Oncology

Cancer is not just “bad cells.” Different cancers have different cell markers. Flow cytometry helps identify those markers.

It is especially useful in blood cancers like:

  • Leukemia
  • Lymphoma
  • Multiple myeloma

Flow can help researchers and clinicians:

  • Detect abnormal cancer cells
  • Classify cancer types
  • Track treatment response
  • Look for small amounts of remaining disease

Think of it like a cell ID scanner for cancer.

  1. Immunotherapy

Immunotherapy uses the immune system to fight disease, especially cancer. Flow cytometry helps scientists understand how immune cells are responding.

It can measure:

  • T cells
  • B cells
  • NK cells
  • Macrophages
  • Activation markers
  • Exhaustion markers
  • Cytokine production

This matters because immunotherapy is not just about whether a treatment works.

It is also about why it works, who it works for, and why it may stop working.

  1. Neuroscience

The brain has more than neurons. It also has immune-like cells that help control inflammation and injury responses.

Flow cytometry is used in neuroscience to study cells like:

  • Microglia
  • Astrocytes
  • Macrophages
  • Infiltrating immune cells

This helps researchers study:

  • Neuroinflammation
  • Brain injury
  • Neurodegenerative disease
  • Immune activity in the nervous system

In simple terms: flow cytometry helps scientists understand what brain cells are doing during disease or injury.

Why It Matters

Flow cytometry is useful because it gives scientists a detailed look at cells one by one.

It can answer questions like:

  • What cells are here?
  • Are they healthy?
  • Are they activated?
  • Are they cancerous?
  • Are they responding to treatment?
  • Did the therapy product come out correctly?

Final Takeaway

  • Flow cytometry is a major tool across modern biotech.
  • It helps researchers and companies understand cells in ways that are fast, detailed, and powerful.
  • Whether the goal is building a cell therapy, studying cancer, testing immunotherapy, or exploring brain inflammation, flow cytometry helps turn complicated cell samples into useful answers.

Why Mitochondrial Heterogeneity is the Next Frontier

Beyond the Powerhouse: Why Mitochondrial Heterogeneity is the Next Frontier in Research (And How to Measure It)

In the world of precision medicine, the ‘average’ is often the enemy of the truth.

It is perhaps the most persistent sentence in biology education: “The mitochondria are the powerhouse of the cell.” While technically true, this singular definition has arguably held back our understanding of these organelles for decades.

Recent explosions in cell biology research have revealed that mitochondria are far more than static energy generators. They are dynamic signaling hubs, gatekeepers of cell death, regulators of immunity, and critical players in aging and neurodegeneration.

But here is the challenge for modern researchers: Mitochondria are not uniform.

If you are researching complex diseases ranging from cancer to metabolic disorders, treating your mitochondrial population as a single, homogenous population is no longer enough. To push your research forward, you need to look at the individual organelle.

The New Era: Mitochondria as Decision Makers

The narrative has shifted. It is no longer just about bioenergetics; it is about cellular governance. We are witnessing a surge in literature identifying mitochondria as the central processing units of the cell, driving critical decisions in:

  • Immune Modulation: Mitochondria are now seen as central to innate immunity, driving signaling cascades that determine how immune cells respond to threats.
  • Cell Fate & Apoptosis: They hold the keys to cell survival, releasing cytochrome c to trigger apoptosis when necessary, or failing to do so in cancer cells.
  • Calcium Buffering & Signaling: They regulate intracellular calcium levels, influencing everything from muscle contraction to neurotransmitter release.
  • Biosynthesis: Distinct subpopulations of mitochondria may prioritize building cellular “blocks” (lipids, proteins) over generating energy, depending on the cell’s immediate needs.

The Bulk Analysis Blind Spot

Despite this complexity, many labs still rely on bulk analysis methods like Western blotting or whole-cell respirometry.

While these methods provide a useful average, they mask the critical details. In a single cell, you might have a subpopulation of healthy, hyper-polarized mitochondria alongside a subpopulation of damaged, depolarized ones. A bulk assay averages these two groups, potentially showing a “normal” result when the reality is a state of cellular crisis.

In diseases like Parkinson’s or Alzheimer’s, where only a fraction of mitochondria may be dysfunctional initially, this averaging effect can hide the very mechanism you are trying to discover.

Enter FAMS: Analyzing the Organelle, Not the Average

At SauveBio, we specialize in FAMS (Fluorescence-Activated Mitochondria Sorting). This isn’t just standard flow cytometry applied to small things; it is a specialized, nanoscale approach that allows us to analyze and sort individual mitochondria.

By treating mitochondria as distinct entities, FAMS allows you to:

  1. Uncover Heterogeneity: distinct subpopulations based on membrane potential, size, or protein expression.

  2. Sort for Downstream Analysis: Isolate the specific “bad actors” (dysfunctional mitochondria) from the healthy pool for sequencing or proteomic analysis.

  3. High-Throughput Sensitivity: Analyze thousands of organelles per second with a level of resolution that microscopy cannot match and bulk assays cannot provide.

The SauveBio Advantage

At SauveBio, we don’t just run samples; we partner with you to design the flow cytometry panels that will answer your specific biological questions. Whether you are investigating the metabolic shift in T-cells or the mitochondrial toxicity of a new drug candidate, FAMS offers the granularity required to publish high-impact data in this evolving field.

Ready to look beyond the powerhouse?

If your research relies on mitochondrial function, stop settling for the average. Contact SauveBio today to discuss how FAMS can reveal the hidden data in your samples.

Our CEO’s Recent Publication: High‑Throughput Organelle‑Level Flow Cytometry

SauveBio is pleased to announce the publication of a cutting-edge study co-authored by our Co‑Founder, CEO & CSO, Dr. Hannah C. Sheehan. The paper, titled “Flow Cytometric Quantification of Mitochondrial Properties: A High‑Throughput Approach for Single Organelle Analysis”, was recently released in the International Journal of Molecular Sciences.

Building on their previously validated method, fluorescence‑activated mitochondria sorting (FAMS), the team utilizes FAMS to allow for detailed, individual-organelle analysis.

Key achievements include:

  • Quantitative enumeration of mitochondrial subpopulations based on size, membrane potential, and surface markers
  • Tracking the translocation of proteins linked to mitophagy, using PINK1 and Parkin probes
  • Detection and characterization of free-floating and extracellular vesicle (EV)–encapsulated mitochondria
  • Measurement of mitochondrial DNA (mtDNA) content alongside functional parameters

This multi-parametric platform offers a powerful new framework for exploring mitochondrial heterogeneity, autophagy, and intercellular organelle signaling – areas of considerable importance to disease research and therapeutic innovation.

 

At SauveBio, we’re excited to see this methodology amplify the resolution of cellular analysis and enrich research across biology, immunology, and therapeutic development. We’re proud to contribute to the advancement of organelle-scale science—and grateful to our co-authors (Piasecki, Tilly, and Woods) and Northeastern University collaborators for bringing this innovation to publication.

📘 Read the full article: International Journal of Molecular Sciences, June 2025, Vol. 26, Issue 12, Article 5481

Piasecki, A.J.; Sheehan, H.C.; Tilly, J.L.; Woods, D.C. Flow Cytometric Quantification of Mitochondrial Properties: A High-Throughput Approach for Single Organelle Analysis. Int. J. Mol. Sci. 2025, 26, 5481. https://doi.org/10.3390/ijms26125481

Blog post by Reagan Cleversey (https://www.linkedin.com/in/reagan-cleversey/)

Unveiling Cellular Mysteries: The Power of Fluorescence Activated Mitochondria Sorting (FAMS)

At SauveBio, we are dedicated to pushing the boundaries of scientific research through innovative technologies. One such groundbreaking technique is Fluorescence Activated Mitochondria Sorting (FAMS), a nanoscale method of flow cytometry that has the power to revolutionize our understanding of mitochondrial biology. Let’s explore the advanced features of FAMS and its contributions to the field, referencing MacDonald et al. 2019 and Sheehan et al. 2023. Our CEO & CSO, Hannah Sheehan, participated in the validation and publication of this method during her time at Northeastern University pursuing her Ph.D. in Biology.

What is FAMS?

Fluorescence Activated Mitochondria Sorting (FAMS) is a cutting-edge technique that leverages the principles of flow cytometry to sort and analyze mitochondria based on their unique fluorescent properties. This method allows researchers to assess mitochondria as individual entities, providing unprecedented insights into mitochondrial heterogeneity and function.

Key Features and Advantages

  1. High Sensitivity and Resolution: FAMS enables the detection and quantification of mitochondrial parameters at the single-organelle level, offering a higher level of sensitivity and resolution than traditional methods. This is crucial for identifying subtle variations in mitochondrial DNA content, membrane potential, and protein expression.
  2. Multiparametric Analysis: The technique allows for the simultaneous measurement of multiple parameters, such as mitochondrial membrane potential, size, and protein expression. This comprehensive view of mitochondrial function is essential for understanding various disease states and aging.
  3. Speed and Efficiency: FAMS can analyze thousands of mitochondria per second, making it a fast and efficient method for studying mitochondrial dynamics. This high throughput capability is particularly beneficial for large-scale studies and clinical applications.
  4. Quantitative Data: The technique provides quantitative data, allowing for precise measurements and comparisons between different samples or experimental conditions. This quantitative approach enhances the reliability and reproducibility of research findings.
  5. Staining of Live Cells for Analysis: FAMS involves staining cells while they are alive, preserving the physiological state of the mitochondria and providing more relevant biological insights. This feature is particularly important for studying mitochondrial function in real-time.

Significant Contributions to the Field

MacDonald et al. 2019 [1]: This study introduced the concept of nanoscale fluorescence-activated mitochondrial sorting (FAMS). This method allows for the sorting of mitochondrial subpopulations with minimal impact on viability while achieving high throughput, yield, and purity. This innovative approach has paved the way for more detailed and accurate analysis of mitochondrial function.

Sheehan et al. 2023 [2]: Building on the advancements of MacDonald et al., Sheehan et al. 2023 further refined the FAMS technique, enabling the separation of individual mitochondria belonging to subpopulations of interest using fluorescent dyes and antibody labeling. This detailed protocol highlighted the significant variability in mitochondrial functional, physical, and chemical attributes, which are relevant to various disease states and aging. By examining mitochondria individually, researchers can gain deeper insights into metabolic disorders, neurodegenerative diseases, and cancer.

Why FAMS Matters to Your Research

FAMS stands apart by enabling the isolation and analysis of distinct mitochondrial subpopulations that whole-cell analysis might overlook. This capability is vital for researchers seeking to understand how specific mitochondrial subpopulations influence disease progression and treatment outcomes. By providing a novel tool to detect differences between samples, FAMS enhances the ability of researchers to conduct high-resolution studies on mitochondrial function and pathology.

Conclusion

Fluorescence Activated Mitochondria Sorting (FAMS) is more than just a technique; it’s a transformative tool that empowers researchers to unlock the mysteries of mitochondrial biology. At SauveBio, we are committed to harnessing the power of FAMS to drive scientific breakthroughs and support our clients’ research endeavors. By leveraging this innovative technology, we aim to accelerate the discovery of new therapeutic targets and improve our understanding of complex diseases.

Ready to elevate your research? Contact SauveBio today to learn how our advanced sorting methods can accelerate your scientific discoveries. 

References 

[1] J.A. MacDonald, A.M. Bothun, S.N. Annis, H. Sheehan, S. Ray, Y. Gao, A.R. Ivanov, K. Khrapko, J.L. Tilly, and D.C. Woods, A nanoscale, multi-parametric flow cytometry-based platform to study mitochondrial heterogeneity and mitochondrial DNA dynamics. Commun Biol 2 (2019) 258.

[2] H.C. Sheehan, J.L. Tilly, and D.C. Woods, Assaying Mitochondrial Function by Multiparametric Flow Cytometry. Methods Mol Biol 2644 (2023) 65-80.